# Imunon, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Imunon, Inc.). ## Overview Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA-based therapies and vaccines. Its lead platform, TheraPlas®, is being advanced for solid tumors such as advanced ovarian cancer, while PlaCCine® is designed for vaccine applications in infectious diseases. ## Products & services • TheraPlas® DNA-based oncology platform • IMNN-001 for advanced ovarian cancer • PlaCCine® vaccine platform • Clinical development and regulatory advancement • CMC/manufacturing support for trial and BLA readiness - **Oncology therapeutics** (70%) — Includes IMNN-001 and related development work for solid tumors, especially advanced ovarian cancer. - **Vaccine platform** (15%) — Includes PlaCCine® programs that code viral antigens for infectious disease vaccines. - **Clinical development and regulatory** (10%) — Includes preclinical, clinical, FDA interaction, and trial advancement activities. - **Manufacturing and CMC** (5%) — Includes process development, potency assay work, and cGMP manufacturing readiness. - TheraPlas® non-viral DNA therapeutic platform - IMNN-001 for newly diagnosed advanced ovarian cancer - PlaCCine® DNA vaccine platform for infectious diseases - Phase 2/Phase 3 clinical development services - cGMP manufacturing and CMC support in Huntsville, Alabama ## Customers Imunon does not yet commercialize products, so its near-term 'customers' are primarily clinical trial sites, investigators, regulators, and future licensing or collaboration partners rather than end-market buyers. If approved, its therapies would be used by oncology specialists and hospitals treating patients with advanced ovarian cancer, and potentially by public health or commercial vaccine channels for PlaCCine® programs. - **Regulators and clinical trial stakeholders** (primary) — The company works with the FDA, trial investigators, and manufacturing reviewers to advance IMNN-001 through development and align on CMC requirements. - **Future biopharma collaboration partners** (primary) — Potential partners may fund, run, or commercialize programs in exchange for rights or shared economics. - **Oncology treatment providers** (secondary) — If approved, hospitals and oncology specialists would use IMNN-001 for advanced ovarian cancer patients. - **Vaccine development partners** (emerging) — PlaCCine® could be licensed or partnered for infectious disease vaccine development and commercialization. - FDA and regulators for clinical and CMC review - Clinical trial investigators and oncology centers - Future pharma partners for development/commercialization - Hospitals and cancer specialists if IMNN-001 is approved - Potential vaccine partners and public health buyers for PlaCCine® ## Geography Imunon is headquartered in the United States and its disclosed operating footprint centers on U.S.-based development and manufacturing. The company specifically referenced manufacturing at its Huntsville, Alabama facility and FDA interactions in the U.S., which makes domestic regulatory execution central to the business. - United States is the core operating and regulatory market - Huntsville, Alabama hosts IMNN-001 clinical-scale manufacturing - FDA meetings and approvals are central to program progress - No meaningful commercial geography yet because products are not sold - Future partnerships could expand geographic reach outside the U.S. ## Strategy Imunon’s strategy is to advance IMNN-001 into a Phase 3 pivotal study, secure FDA alignment on clinical and CMC requirements, and preserve optionality through collaborations. Because the company has not commercialized products and has limited cash, financing, partnership, and grant execution are as important as clinical progress. - **Advance IMNN-001 into Phase 3** (short-term) — Clinical proof-of-concept and pivotal data are the main value drivers for a pre-revenue biotech. - **Secure financing and non-dilutive support** (short-term) — The company has limited cash and substantial going-concern risk, so funding determines operating continuity. - **Build partnership optionality** (medium-term) — Collaborations can reduce capital needs and accelerate development or commercialization. - Advance IMNN-001 into Phase 3 for advanced ovarian cancer - Use FDA alignment to reduce development and approval risk - Pursue collaborations to share cost and commercialization burden - Seek equity, licensing, and grant funding to extend runway - Maintain manufacturing readiness for future BLA submission ## Risks Imunon is a pre-revenue clinical-stage biotech, so its main risks are clinical failure, regulatory delay, and financing shortfalls. The company also faces going-concern risk, dilution from equity issuance, and Nasdaq listing risk if it cannot maintain compliance or raise capital on acceptable terms. - **Going-concern and liquidity shortfall** [critical] — The company disclosed substantial doubt about its ability to continue without additional capital. - **Clinical development failure** [high] — Drug research and development is inherently uncertain and pivotal studies can fail at any stage. - **Financing dilution and unfavorable terms** [high] — The company relies on equity, partnerships, and grants, which may be unavailable or dilutive. - **Regulatory and CMC execution risk** [high] — FDA alignment on manufacturing, potency assays, and comparability is required for Phase 3 and BLA readiness. - **Nasdaq listing compliance** [medium] — Failure to meet continued listing standards could lead to delisting and reduced liquidity. - No product revenue yet; value depends on clinical and regulatory success - Going-concern risk due to limited cash and ongoing operating losses - Dilution risk from ATM and other equity financings - Clinical trial setbacks could materially delay or end programs - Nasdaq delisting risk if listing standards are not met ## Accounting The key accounting issue is that Imunon is not yet generating product revenue, so reported results are driven by R&D expense, financing activities, and cash burn rather than sales recognition. Investors should also watch going-concern disclosures, stock issuance accounting, and any future collaboration or grant accounting because these can materially affect dilution, liquidity presentation, and period-to-period comparability. - **Going-concern assessment** — May require additional disclosures and highlights liquidity risk - **Equity issuance and dilution** — Increases dilution and can pressure valuation - **Collaboration and licensing accounting** — Could shift reported revenue and deferred income - **Grant and subsidy recognition** — Could reduce net loss in periods received - No product revenue yet, so losses are driven by R&D and G&A spending - Going-concern disclosure affects asset and liability presentation - ATM equity issuance changes share count and dilution - Future collaborations may require deferred revenue or milestone accounting - Grant or subsidy accounting could offset R&D expense if awarded --- *Last updated: 2026-04-28T20:17:06.653635+00:00*